3-(N-benzylsulfamoyl)-4-bromo-N-(4-bromophenyl)benzamide: stimulates RAD51 DNA-binding activity to promote cancer cell death; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 1039737 |
| CHEMBL ID | 1598912 |
| SCHEMBL ID | 13186460 |
| MeSH ID | M000598928 |
| Synonym |
|---|
| EU-0034229 |
| NCGC00141035-01 |
| OPREA1_698256 |
| OPREA1_166111 |
| RS1 , |
| HMS1917E02 |
| AKOS000731000 |
| 3-(benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide |
| STL170129 |
| 3-[(benzylamino)sulfonyl]-4-bromo-n-(4-bromophenyl)benzamide |
| rs-1 |
| 312756-74-4 |
| rad51-stimulatory compound-1, rs-1 |
| S8234 |
| CHEMBL1598912 |
| SCHEMBL13186460 |
| 4-bromo-n-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]benzamide |
| AC-35367 |
| 3-(n-benzylsulfamoyl)-4-bromo-n-(4-bromophenyl)benzamide |
| HY-19793 |
| sr-01000395441 |
| SR-01000395441-1 |
| EX-A1010 |
| DTXSID80359902 |
| CS-5642 |
| rad51-stimulatory compound-1 |
| benzamide, 4-bromo-n-(4-bromophenyl)-3-[[(phenylmethyl)amino]sulfonyl]- |
| rs-1, >=98% (hplc) |
| J-018355 |
| mfcd00348720 |
| A16153 |
| BCP18095 |
| c20h16n2o3sbr2 |
| HB5647 |
| 4-bromanyl-n-(4-bromophenyl)-3-[(phenylmethyl)sulfamoyl]benzamide |
| J46 , |
| CP-0069 |
| CCG-96390 |
| A912272 |
| 4-bromo-n-(4-bromophenyl)-3-(((phenylmethyl)amino)sulfonyl)benzamide |
| R0215 |
| Z275140708 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 12.5893 | 0.1800 | 13.5574 | 39.8107 | AID1468 |
| Smad3 | Homo sapiens (human) | Potency | 12.5893 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| PINK1 | Homo sapiens (human) | Potency | 50.1187 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| 67.9K protein | Vaccinia virus | Potency | 28.1838 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
| Parkin | Homo sapiens (human) | Potency | 50.1187 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 15.6739 | 0.3162 | 12.4435 | 31.6228 | AID902; AID903; AID924 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 31.6228 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 11.2202 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 11.2202 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 0.5623 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1178406 | Induction of RAD51 in cisplatin-treated neonatal human skin fibroblast assessed as increase in survival at 7.5 uM relative to untreated control | 2014 | Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14 | Targeting the homologous recombination pathway by small molecule modulators. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||